The markets traded lower during the midday with the Dow easing 6 points to 15,969 as compensation costs for the nation's employees rose in the third quarter. Nasdaq fell 17 points to 3931.
On the upside
A Seeking Alpha contributor said that the Food and Drug Administration erred when it rescinded Amarin's (Nasdaq: IPCI) ANCHOR special protocol assessment agreement.
Spherix (Nasdaq: SPEX) settled a patent infringement dispute and entered a license agreement with a technology firm.
Aegis Capital initiated coverage of Evoke Pharma (Nasdaq: EVOK) with a Buy rating.
On the downside
LightInTheBox (NYSE: LITB) widened third quarter losses more than expected as expenses soared.
Motley Fool wrote that Voxeljet (NYSE: VJET) was overvalued.
A senator from Alabama questioned government grants that were awarded to SolarCity (Nasdaq: SCTY).
In the broad market, declining issues outpaced advancers by a margin of more than 2 to 1 on the NYSE and by more than 3 to 2 on Nasdaq. The broader S&P 500 lost 4 points to 1787.
